The findings suggest that women who experience early menopause (age <40 vs >50 years) may constitute a sex-specific high-risk group for cognitive decline.

Interventions to protect or improve auditory health across the lifespan could be a cost-effective means of slowing the rapid rise of dementia in the US, authors wrote.

Novavax’s COVID-19 vaccine was linked to fewer and less severe side effects vs mRNA in a University of Utah study of health care workers.

An interview with Jeff Andrews, MD, FRCSC, of BD Life Sciences

Your daily dose of the clinical news you may have missed.

ACP 2025: Dr Kalager shares strategies for addressing patient beliefs, presenting risk data, and promoting shared decision-making in primary care settings.

The global prevalence of AD in older adults increased by 107% between 1990 and 2021, with a greater burden among women and in high sociodemographic regions.

ACP 2025: Collaborative care can help address the mental health crisis, but payment and EHR challenges remain. Matthew Press, MD, explains how primary care can overcome these barriers and why integration is essential.

Your daily dose of the clinical news you may have missed.

The CART ring was superior to the Apple Watch in automated AF detection with fewer unclassified ECGs, but neither device should serve as a definitive diagnostic tool.

Respiratory syncytial virus was deadly and untreatable across the lifespan until 2023 when the first vaccines were approved in the US. Follow the timeline, here.

ACP 2025. The timely glucose data available with continuous glucose monitoring is what's needed for optimal daily diabetes control, says Tom Martens, MD.

The increase in pancreatic cancer among Americans aged 15 to 34 is particularly alarming and should alert clinicians to heed relevant GI symptoms as suspicious.

Dupilumab (Dupixent) is the first new targeted therapy for CSU in over a decade.

The phone-based patient navigation intervention addressed barriers to CRC testing follow-up and included patient education.

New data highlight the potential of dupilumab, remibrutinib, and barzolvolimab to expand treatment options for patients with CSU unresponsive to current therapies.

Pooled data from the OASIS clinical trial program showed consistent efficacy of elinzanetant across BMI and smoking history subgroups, highlighting its broad applicability.

The mildly elevated glycemia of prediabetes is a pathological condition with serious risks for those 77 million, says endocrinologist Samuel Dagogo-Jack, MD, DSc.

The positive topline data from the phase 3 ACHIEVE-1 trial suggest the small molecule GLP-1 mimetic could compete with blockbuster weekly injectables for reducing weight, A1c.